Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management
2026-03-18
Mary E. Rinella, Silvia Sookoian
Nature Reviews Gastroenterology & Hepatology, Published online: 18 March 2026; doi:10.1038/s41575-026-01187-8 Current drug approvals reshape metabolic dysfunction-associated steatohepatitis (MASH) therapeutic strategies. This Review highlights current and emerging therapeutic targets and discusses a mechanism-based framework for personalized, combination-oriented management in MASH.